Cancer Prevention Pharmaceuticals, Sucampo deal

Cancer Prevention granted Sucampo an exclusive option to exclusively develop and commercialize CCP-1X/sulindac in North America. Cancer Prevention will complete the ongoing Phase III trial of CPP-1X/sulindac to treat familial adenomatous polyposis (FAP) under a joint steering committee. The company expects to complete enrollment this half. CPP-1X/sulindac is a combination of eflornithine (difluoromethylornithine, DFMO), a selective inhibitor of ornithine decarboxylase (ODC), and sulindac, a generic NSAID, in a Phase III trial to treat sporadic colon adenoma. ...